Inozyme Pharma News

RMBS, SANM and WGS Are Among After Hour Movers

Seeking AlphaApr 29 17:00 ET

12 Health Care Stocks Moving In Monday's After-Market Session

GainersGeneDx Hldgs (NASDAQ:WGS) shares increased by 21.8% to $13.4 during Monday's after-market session. The market value of their outstanding shares is at $349.1 million. The company's, Q1 earnings

BenzingaApr 29 16:31 ET

Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Shares of Tilray Brands, Inc. (NASDAQ:TLRY) fell sharply during Tuesday's session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free cas

BenzingaApr 9 13:12 ET

Inozyme Pharma Is Maintained at Buy by B of A Securities

Inozyme Pharma Is Maintained at Buy by B of A Securities

Dow JonesApr 9 12:47 ET

B of A Securities Maintains Buy on Inozyme Pharma, Lowers Price Target to $14

B of A Securities analyst Tazeen Ahmad maintains Inozyme Pharma with a Buy and lowers the price target from $16 to $14.

Analyst UpgradesApr 9 12:38 ET

Express News | Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target

Moomoo 24/7Apr 9 07:56 ET

Inozyme Pharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/09/2024 298.61% Needham → $23 Reiterates Buy → Buy 03/13/2024 177.3% HC Wainwright & Co. $16 → $16 Main

BenzingaApr 9 07:53 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)

TipRanksApr 9 06:20 ET

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)

TipRanksApr 9 05:40 ET

Inozyme Pharma Announces Positive Topline Data From Ongoing Phase 1/2 Trials of INZ-701 in Adults...

Stockhouse Apr 8 06:30 ET

Inozyme Pharma Announces Positive Topline Data From Ongoing Phase 1/2 Trials of INZ-701 in Adults With ABCC6 Deficiency (PXE) and ENPP1 Deficiency

Yahoo FinanceApr 8 06:30 ET

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of

GlobeNewswireApr 5 18:00 ET

Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of

GlobeNewswireApr 2 08:30 ET

Top 5 Health Care Stocks That May Plunge In March

As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicat

BenzingaMar 28 08:30 ET

ANGI, MLKN and KOD Are Among After Hour Movers

Seeking AlphaMar 27 16:50 ET

Express News | Inozyme Pharma Shares Are Trading Higher After the Company Announced That It Will Discuss Topline Data From Its Ongoing Phase 1/2 Trial of INZ-701 in Adults With ABCC6 Deficiency, and From All Cohorts of Its Ongoing Phase 1/2 Trial of INZ-701 in Adults Wi

Moomoo 24/7Mar 26 10:51 ET

Express News | Inozyme Pharma To Report Topline Data From Ongoing Phase 1/2 Trials Of INZ-701 In Adults With ABCC6 Deficiency And ENPP1 Deficiency On April 8, 2024

Moomoo 24/7Mar 26 08:31 ET

Inozyme Pharma: A Promising Buy Amid Anticipated Clinical Breakthroughs and Financial Stability

TipRanksMar 14 05:47 ET

Inozyme Pharma Is Maintained at Buy by HC Wainwright & Co.

Inozyme Pharma Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMar 13 09:39 ET

Express News | HC Wainwright & Co. Maintains Buy on Inozyme Pharma, Maintains $16 Price Target

Moomoo 24/7Mar 13 09:29 ET